Review Article
The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease

https://doi.org/10.1016/j.yjmcc.2004.05.015Get rights and content

Abstract

Phosphoinositide-3 kinases (PI3Ks) are a family of evolutionary conserved lipid kinases that mediate many cellular responses in both physiologic and pathophysiologic states. Class I PI3K can be activated by either receptor tyrosine kinase (RTK)/cytokine receptor activation (class IA) or G-protein-coupled receptors (GPCR) (class IB). Once activated PI3Ks generate phosphatidylinositols (PtdIns) (3,4,5)P3 leading to the recruitment and activation of Akt/protein kinase B (PKB), PDK1 and monomeric G-proteins (e.g. Rac-GTPases), which then activate a range of downstream targets including glycogen synthase kinase-3β (GSK-3β), mammalian target of rapamycin (mTOR), p70S6 kinase, endothelial nitric oxide synthase (eNOS) and several anti-apoptotic effectors. Class IA (PI3Kα, β and δ) and class IB (PI3Kγ) PI3Ks mediate distinct phenotypes in the heart and under negative control by the 3′-lipid phosphatase, phosphatase and tensin homolog on chromosome ten (PTEN) which dephosphorylate PtdIns(3,4,5)P3 into PtdIns(4,5)P2. PI3Kα, γ and PTEN are expressed in cardiomyocytes, fibroblasts, endothelial cells and vascular smooth muscle cells where they modulate cell survival/apoptosis, hypertrophy, contractility, metabolism and mechanotransduction. Several transgenic and knockout models support a fundamental role of PI3K/PTEN signaling in the regulation of myocardial contractility and hypertrophy. Consequently the PI3K/PTEN signaling pathways are involved in a wide variety of diseases including cardiac hypertrophy, heart failure, preconditioning and hypertension. In this review, we discuss the biochemistry and molecular biology of PI3K (class I isoforms) and PTEN and their critical role in cardiovascular physiology and diseases.

Section snippets

Phosphatidylinositol metabolism

Phosphatidylinositols (PtdIns) are phospholipids that are comprised of a phosphoglyceride esterified to the hydroxyl group of inositol (Fig. 1A). The inositol ring can be phosphorylated and dephosphorylated at various positions by an array of lipid kinases and phosphatases (Fig. 1B) [1], [2], [3]. Phosphatidylinositol-4-phosphate (i.e. PtdIns(4)P) and phosphatidylinositol-4,5-phosphate (i.e. PtdIns(4,5)P2) are the major phosphorylated PtdIns present at basal conditions which are reported to

Structure and function of PI3Ks

PI3Ks are divided into three classes according to their substrate specificity, mode of activation and molecular structure [1], [3], [12], [13] (Table 1). Our review will focus on class IA and IB PI3Ks which are heterodimeric enzymes composed of a regulatory adapter (accessory) subunit coupled to a tightly bound catalytic subunit [3], [12], [13]. Class IA catalytic subunits include p110α, β and δ while the class IB catalytic subunit is p110γ (Table 1) [3], [13]. The class IA PI3K adapter

PTEN—3′-lipid phosphatase and a negative regulator of PI3Ks

Phosphoinositide phosphatases are divided into three different families. The CX5R family contains PTEN and myotubularin (MTM) which are 3′- and 4′-phosphatases while SHIP-1 and -2 are 5′-phosphatases [3]. PTEN is also known as “mutated in multiple advanced cancers” (MMAC1) as well as the TGFβ-regulated and epithelial cell-enriched phosphatase (TEP1), and was first identified as tumor-suppressor gene localized on chromosome 10q23 [3], [19], [62]. Somatic mutations in PTEN are often found in many

Molecular targets of PI3K/PTEN signaling

PI3K/PTEN are the primary regulators of PtdIns(3,4,5)P3 and PtdIns(3,4)P2 (and PtdIns(4,5)P2) which mediate selective targeting and activation of many downstream effectors by binding to PH, FYVE (named after four proteins containing this domain: Fab1, YOTB, Vac1 and EEA1), phox homology (PX), epsin N-terminal homology (ENTH), SH2 and C2 domains [3], [100], [101], [102]. The PH domain is of particular importance and consist of about 120 amino acids residues having a unique three-dimensional

Cell survival and apoptosis

PI3K activation enhances cell survival and antagonizes apoptosis via Akt/PKB in many cell types including cardiomyocytes [148], [149], [150], cardiac fibroblast [151], VSMCs [152] and endothelial cells [126], [150]. Consistent with Akt/PKB multi-compartment signaling [123], [124], anti-apoptotic action of Akt/PKB involve both cytoplasmic and nuclear compartments via modulation of bad, caspase-3, caspase-3, Forkhead transcription factors and IκB kinase [121], [122], [153], [154]. Growth factors

Isoform-specific signaling by class I PI3K: interaction with PTEN

Cell signaling involves spatial and temporal integration of multiple signaling pathways [32], [47], [188], [244] as illustrated in the heart with intracellular Ca2+ [188], [245], cAMP [185], [186], [188] and NO signaling [201]. Recent studies have established that PI3K/PTEN signaling is also spatially and functionally restricted in many cell types including cardiomyocytes [36], [197], fibroblasts [32], [246], neutrophils [247], neurons [122] and breast cancer cells [248] Under basal conditions,

Role of PI3K in preconditioning

Ischemic preconditioning (IPC) refers to a phenomenon where brief periods of mild ischemia can protect the heart from subsequent ischemia. Acute IPC lasts approximately 2 h while a second window of protection (i.e. delayed IPC) develops 24 h later and lasts approximately 3 d [269], [270]. Preconditioning involves the release of several autacoids that trigger protection by activating various receptors, cell signaling cascades and effectors [269], [271], [272], [273]. In acute IPC there is

Role of PI3K and PTEN in heart failure

PI3K/Akt and several downstream pathways are activated in heart disease including myocardial ischemia/reperfusion [276], [277], [281], [282], diabetic-associated cardiomyopathy [170], [283], adriamycin-induced cardiomyopathy [159], [284], chronic β-AR stimulation [40], [178], pressure-overload-induced hypertrophy [156], [172], [176] and in advanced human heart failure [243], [285]. However, class IA and IB PI3K isoforms appear to have distinct roles in the pathogenesis of heart disease. Animal

PI3K and PTEN in vascular function and diseases

Both class IA (PI3Kα and β) and IB (PI3Kγ) isoforms, lipid phosphatases (PTEN and SHIP2) [23], [39], [41], [42], [86], [214], [314] and several downstream targets of PI3K including Akt1/PKBα, Akt2/PKBβ, Akt3/PKBγ, GSK3α/β and mTOR/p70S6K1 have been shown to be expressed in VSMCs [39], [125], [145], [315]. PI3K/Akt and PTEN are involved in both cytosolic and nuclear signaling in endothelial and VSMCs where they regulate vascular homeostasis and angiogenesis, as well as VSMC growth and

Pharmacologic inhibitors of PI3K

The pharmacologic inhibitors of PI3Ks have been useful tools in advancing our understanding of the biology of PI3Ks. WM and LY294002, the two most widely used PI3K inhibitors, are low-molecular-weight and cell-permeable compounds that are structurally and mechanistically distinct antagonists of all three classes of PI3Ks. WM was originally isolated from Penicillium wortmannii and irreversibly inactivates the PI3Ks by covalent modification of the catalytic subunit, p110 [3], [333], [334].

Future perspectives

The diverse effects mediated by PI3K/PTEN signaling in the heart and vasculature clearly support an important biologic and pathophysiologic role for this signaling cascade. This has provided great hope for future therapies for hypertension, vascular restenosis, ischemia/reperfusion injury and congestive heart failure. The distinct roles of class IA and IB PI3K isoforms suggest that therapeutic manipulation of PI3K/PTEN system may require isoform specific targeting. However, many aspects of

Acknowledgements

We acknowledge the financial support from the Canadian Institute for Health Research (P.H.B.) and Heart and Stroke Foundation of Ontario (P.H.B.). G.Y.O. is a recipient of a Post-Doctoral Fellowship from the Canadian Institute for Health Research and the Heart and Stroke Foundation of Canada and is a Fellow of the TACTICS program. P.H.B. is a Career Investigator of the Heart and Stroke Foundation of Ontario.

References (346)

  • L.J Pike et al.

    Cholesterol depletion delocalizes phosphatidylinositol bisphosphate and inhibits hormone-stimulated phosphatidylinositol turnover

    J Biol Chem

    (1998)
  • Y Liu et al.

    Compartmentalization of phosphatidylinositol 4,5-bisphosphate in low-density membrane domains in the absence of caveolin

    Biochem Biophys Res Commun

    (1998)
  • J.R Halstead et al.

    A novel pathway of cellular phosphatidylinositol(3,4,5)-trisphosphate synthesis is regulated by oxidative stress

    Curr Biol

    (2001)
  • J Laporte et al.

    The myotubularin family: from genetic disease to phosphoinositide metabolism

    Trend Genet

    (2001)
  • Y.J Wang et al.

    Phosphatidylinositol 4 phosphate regulates targeting of clathrin adaptor AP-1 complexes to the Golgi

    Cell

    (2003)
  • P Deleris et al.

    SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear specklesy

    J Biol Chem

    (2003)
  • K Tanaka et al.

    Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in nucleus

    J Biol Chem

    (1999)
  • A Metjian et al.

    Agonists cause nuclear translocation of phosphatidylinositol 3-kinase gamma. A Gbetagamma-dependent pathway that requires the p110gamma amino terminus

    J Biol Chem

    (1999)
  • E Quist et al.

    Regulation of polyphosphoinositide synthesis in cardiac membranes

    Arch Biochem Biophys

    (1989)
  • S Cockcroft

    Mammalian phosphatidylinositol transfer proteins: emerging roles in signal transduction and vesicular traffic

    Chem Phys Lipid

    (1999)
  • B.D Hamman et al.

    Binding of a pleckstrin homology domain protein to phosphoinositide in membranes: a miniaturized FRET-based assay for drug screening

    J Biomol Screen

    (2002)
  • I.C Schneider et al.

    Spatial analysis of 3′ phosphoinositide signaling in living fibroblasts: II. Parameter estimates for individual cells from experiments

    Biophys J

    (2004)
  • M.A Crackower et al.

    Regulation of myocardial contractility and cell size by distinct PI3K-PTEN signaling pathways

    Cell

    (2002)
  • L.R Stephens et al.

    The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101

    Cell

    (1997)
  • D Bacqueville et al.

    Characterization of a G protein-activated phosphoinositide 3-kinase in vascular smooth muscle cell nuclei

    J Biol Chem

    (2001)
  • J.F Quignard et al.

    Phosphoinositide 3-kinase gamma mediates angiotensin II-induced stimulation of L-type calcium channels in vascular myocytes

    J Biol Chem

    (2001)
  • K Cieslik et al.

    Up-regulation of endothelial nitric-oxide synthase promoter by the phosphatidylinositol 3-kinase gamma/Janus kinase 2/MEK-1-dependent pathway

    J Biol Chem

    (2001)
  • T Pawson

    Specificity in signal transduction. From phosphotyrosine-SH2 domain interactions to complex cellular systems

    Cell

    (2004)
  • J Schlessinger

    Cell signaling by receptor tyrosine kinases

    Cell

    (2000)
  • C Czupalla et al.

    Identification and characterization of the autophosphorylation sites of phosphoinositide 3-kinase isoforms beta and gamma

    J Biol Chem

    (2003)
  • L Bi et al.

    Proliferative defect and embryonic lethality in mice homozygous for a deletion in the p110 alpha subunit of phosphoinositide 3-kinase

    J Biol Chem

    (1999)
  • N.R Leslie et al.

    PTEN: the down side of PI 3-kinase signalling

    Cell Signal

    (2002)
  • V Stambolic et al.

    Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

    Cell

    (1998)
  • F Vazquez et al.

    Phosphorylation of the PTEN tail acts as an inhibitory switch by preventing its recruitment into a protein complex

    J Biol Chem

    (2001)
  • R.B Campbell et al.

    Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate

    J Biol Chem

    (2003)
  • S.R Lee et al.

    Reversible inactivation of the tumor suppressor PTEN by H2O2

    J Biol Chem

    (2002)
  • G Schwartzbauer et al.

    The tumor suppressor gene PTEN can regulate cardiac hypertrophy and survival

    J Biol Chem

    (2001)
  • L Patel et al.

    Tumor suppressor and anti-inflammatory actions of PPARgamma agonists are mediated via upregulation of PTEN

    Curr Biol

    (2001)
  • S Kim et al.

    Down-regulation of the tumor suppressor PTEN by the TNFalpha /NIK/NF-kappa B pathway is linked to a default Ikappa B-alpha autoregulatory loop

    J Biol Chem

    (2004)
  • X Gao et al.

    Drosophila PTEN regulates cell growth and proliferation through PI3K-dependent and -independent pathways

    Dev Biol

    (2000)
  • S Ogg et al.

    The C elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway

    Mol Cell

    (1998)
  • T Maehama et al.

    The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate

    J Biol Chem

    (1998)
  • J Huang et al.

    PTEN modulates vascular endothelial growth factor-mediated signaling and angiogenic effects

    J Biol Chem

    (2002)
  • A Suzuki et al.

    High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice

    Curr Biol

    (1998)
  • S.A Kim et al.

    Myotubularin and MTMR2, phosphatidylinositol 3-phosphatases mutated in myotubular myopathy and type 4B Charcot-Marie-Tooth disease

    J Biol Chem

    (2002)
  • M.J Aman et al.

    The inositol phosphatase SHIP inhibits Akt/PKB activation in B cells

    J Biol Chem

    (1998)
  • M.P Scheid et al.

    Unravelling the activation mechanisms of protein kinase B/Akt

    FEBS Lett

    (2003)
  • M.J Bottomley et al.

    Phospholipid-binding protein domains

    Biochim Biophys Acta

    (1998)
  • B Vanhaesebroeck et al.

    Synthesis and function of 3-phosphorylated inositol lipids

    Annu Rev Biochem

    (2001)
  • D.A Fruman et al.

    Phosphoinositide kinases

    Annu Rev Biochem

    (1998)
  • Cited by (416)

    • Mechanisms of Cardiac Repair in Cell Therapy

      2023, Heart Lung and Circulation
    View all citing articles on Scopus
    View full text